© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses how dosing adjustments may be used to increase the efficacy of agents, such as cetuximab (Erbitux) in patients with head and neck cancer.